Skip to content

Clinical study of dexmedetomidine in the management of prone position ventilation in patients with COVID-19 pneumonia: a single-center, prospective, randomized, double-blind, controlled study

Clinical study of dexmedetomidine in the management of prone position ventilation in patients with COVID-19 pneumonia: a single-center, prospective, randomized, double-blind, controlled study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300067383
Enrollment
Unknown
Registered
2023-01-05
Start date
2023-01-06
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Common COVID-19 pneumonia

Interventions

Group 1:Normal saline intravenous pumping

Sponsors

Medical Ethics Committee of Shanghai Fourth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Common COVID-19 pneumonia; 2. Age >= 65years old; 3. Voluntarily sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe liver dysfunction (Child-Pugh class C); Severe renal insufficiency (requiring dialysis); 2. Unable to complete the prone position (patients with hemodynamic instability, severe obesity (BMI > 40 kg/m2), pregnant women, or patients with spinal fracture, esophageal surgery, high risk of pressure ulcers, etc.); 3. Inability to ventilate in prone position in patients with a mental disorder; 4. Left ventricular ejection fraction < 30%, sick sinus syndrome, severe sinus bradycardia (<50 beats/min), or atrioventricular block grade II or higher without a pacemaker; 5. Participated in another clinical trial within 3 months before enrollment.

Design outcomes

Primary

MeasureTime frame
Rate of completion of prone position ventilation for cumulative 9 hours per day;

Secondary

MeasureTime frame
Completion rate of 12-hour duration of prone position ventilation;Rate of conversion to severe pneumonia;Hemodynamic indexes (Blood pressure, heart rate);Number of vasoactive drug interventions;Improvement of infection indicators (CRP, IL-6, PCT, blood routine);Improvement of SpO2;Rate of tracheal intubation and mortality during hospitalization;30-day mortality;Length of stay;Oxygenation index;normal tissue complication probability;

Countries

China

Contacts

Public ContactXiong Lize

Shanghai Fourth People's Hospital affiliated to Tongji University

mzkxlz@126.com+86 136 0928 3068

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026